B细胞靶向治疗对慢性淋巴细胞白血病患者SARS-CoV-2疫苗效力的影响
本研究评估了慢性淋巴细胞白血病(CLL)患者接种SARS-CoV-2疫苗后的免疫应答,发现与健康对照相比,接种疫苗的CLL患者血清转换率降低且抗S抗体水平更低,中和活性测定与Roche抗S检测结果一致。正常B细胞缺失(常见于接受布鲁顿酪氨酸激酶和B细胞淋巴瘤2抑制剂治疗的患者)是缺乏血清转换的强预测因素。
要点
- 接种疫苗的CLL患者血清转换率低于健康对照,抗S抗体水平也更低。
- Roche抗S检测与中和活性测定结果一致。
- 正常B细胞缺失是缺乏血清转换的强预测因素。
核心结论
- 接种疫苗的CLL患者血清转换率降低,抗S抗体水平低于健康对照,中和活性测定与Roche抗S检测结果一致。
- 正常B细胞缺失是缺乏血清转换的强预测因素。
研究设计与样本
- 研究比较了接种SARS-CoV-2疫苗的慢性淋巴细胞白血病(CLL)患者与健康对照的免疫应答。
- 采用Roche抗S检测和中和活性测定评估体液免疫。
主要发现
- 与健康对照相比,接种疫苗的CLL患者血清转换率降低,抗S抗体水平更低。
- Roche抗S检测与中和活性测定结果相似。
- 在六个月时观察到持久应答;在应答患者中可能通过加强针增强免疫。
- 正常B细胞缺失(常见于接受布鲁顿酪氨酸激酶和B细胞淋巴瘤2抑制剂治疗的患者)是缺乏血清转换的强预测因素。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prior reports evaluating SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemia (CLL) used semiquantitative measurements of anti-S to evaluate immunity; however, neutralization assays were used to assess functional immunity in the trials leading to vaccine approval. Here, we identified decreased rates of seroconversion in vaccinated CLL patients and lower anti-S levels compared to healthy controls. Notably, we demonstrated similar results with the Roche anti-S assay and neutralization activity. Durable responses were seen at six months; augmentation with boosters was possible in responding patients. Absence of normal B cells, frequently seen in patients receiving Bruton tyrosine kinase and B-cell lymphoma 2 inhibitors, was a strong predictor of lack of seroconversion.
引用
- Ujjani C, Shadman M, Lynch RC, et al. The impact of B-cell-directed therapy on SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemia. Br J Haematol. 2022. PMID: 35149986. doi:10.1111/bjh.18088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。